A 69-Year-Old Woman with Intermittent Claudication and Elevated ESR
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Vasculitis: Pearls for Early Diagnosis and Treatment of Giant Cell Arteritis
Vasculitis: Pearls for early diagnosis and treatment of Giant Cell Arteritis Mary Beth Humphrey, MD, PhD Professor of Medicine McEldowney Chair of Immunology [email protected] Office Phone: 405 271-8001 ext 35290 October 2019 Relevant Disclosure and Resolution Under Accreditation Council for Continuing Medical Education guidelines disclosure must be made regarding relevant financial relationships with commercial interests within the last 12 months. Mary Beth Humphrey I have no relevant financial relationships or affiliations with commercial interests to disclose. Experimental or Off-Label Drug/Therapy/Device Disclosure I will be discussing experimental or off-label drugs, therapies and/or devices that have not been approved by the FDA. Objectives • To recognize early signs of vasculitis. • To discuss Tocilizumab (IL-6 inhibitor) as a new treatment option for temporal arteritis. • To recognize complications of vasculitis and therapies. Professional Practice Gap Gap 1: Application of imaging recommendations in large vessel vasculitis Gap 2: Application of tocilizimab in treatment of giant cell vasculitis Cranial Symptoms Aortic Vision loss Aneurysm GCA Arm PMR Claudication FUO Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Which is not a risk factor or temporal arteritis? A. Smoking B. Female sex C. Diabetes D. Northern European ancestry E. Age Giant Cell Arteritis • Most common form of systemic vasculitis in adults – Incidence: ~ 1/5,000 persons > 50 yrs/year – Lifetime risk: 1.0% (F) 0.5% (M) • Cause: unknown At risk: Women (80%) > men (20%) Northern European ancestry>>>AA>Hispanics Age: average age at onset ~73 years Smoking: 6x increased risk Kermani TA, et al Ann Rheum Dis. -
Jordan M. Garrison, Md Facs Fasmbs What Are We Talking About?
PERIPHERAL VASCULAR DISEASE JORDAN M. GARRISON, MD FACS FASMBS WHAT ARE WE TALKING ABOUT? Peripheral Arterial Disease (PAD) • Near or Complete obstruction of > 1 Peripheral Artery Peripheral Venous Reflux Disease • Varicose Veins • Chronic Venous Stasis Ulcer Disease • Phlegmasia Cerulia Dolans or Alba Dolans (Milk Leg) • Deep Vein Thrombosis and Pulmonary Embolus Disease Coronary Artery Disease ◦ Myocardial Infarct Aneurysmal Disease • Aortic • Popliteal Cerebral and Carotid Artery Disease • Stroke • TIA Renal Vascular Hypertensive Disease • High Blood Pressure • Kidney Failure Peripheral Arterial Disease PREVELANCE Males > Females 10% of People over 60 Race • AA double the rate of all other ethnicities High Income Countries Peripheral Arterial Disease RISK FACTORS Smoking is the #1 risk factor Diabetes Mellitus Diet Obesity ETOH Cholesterol Heredity Lifestyle Homocysteine, C Reactive Protein, Fibrinogen Arterial Anatomy Lower Extremity Anatomy Plaque Formation Plaque Peripheral Arterial Disease Claudication • Disabling • Intestinal Limb Threatening Ischemia(LTI) Critical Limb Ischemia(CLI) • Rest Pain • Tissue Loss • Gangrene Disabling Claudication Intestinal Ischemia Intestinal Claudication Peripheral Arterial Disease Claudication • Disabling • Intestinal Limb Threatening Ischemia(LTI) Critical Limb Ischemia(CLI) • Rest Pain • Tissue Loss • Gangrene Rest Pain/ Dependent Rubor Tissue Loss Gangrene Peripheral Artery Disease Diagnosis Segmental Pressures • Lower extremity Blood Pressures ABI • Nl >1.0, Diabetes will give elevated reading -
Guideline-Management-Giant-Cell
Arthritis Care & Research Vol. 73, No. 8, August 2021, pp 1071–1087 DOI 10.1002/acr.24632 © 2021 American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis Mehrdad Maz,1 Sharon A. Chung,2 Andy Abril,3 Carol A. Langford,4 Mark Gorelik,5 Gordon Guyatt,6 Amy M. Archer,7 Doyt L. Conn,8 Kathy A. Full,9 Peter C. Grayson,10 Maria F. Ibarra,11 Lisa F. Imundo,5 Susan Kim,2 Peter A. Merkel,12 Rennie L. Rhee,12 Philip Seo,13 John H. Stone,14 Sangeeta Sule,15 Robert P. Sundel,16 Omar I. Vitobaldi,17 Ann Warner,18 Kevin Byram,19 Anisha B. Dua,7 Nedaa Husainat,20 Karen E. James,21 Mohamad A. Kalot,22 Yih Chang Lin,23 Jason M. Springer,1 Marat Turgunbaev,24 Alexandra Villa-Forte, 4 Amy S. Turner,24 and Reem A. Mustafa25 Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particu- lar patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. -
Crohn's Disease
Harvard-MIT Division of Health Sciences and Technology HST.121: Gastroenterology, Fall 2005 Instructors: Dr. Jonathan Glickman Vascular and Inflammatory Diseases of the Intestines Overview • Vascular disorders – Vascular “malformations” – Vasculitis – Ischemic disease • Inflammatory disorders of specific etiology – Infetious enterocolitis – “Immune-mediated” enteropathy – Diverticular disease • Idiopathic inflammatory bowel disease – Crohn’s disease – Ulcerative colitis Sporadic Vascular Ectasia (Telangiectasia) • Clusters of tortuous thin-walled small vessels lacking muscle or adventitia located in the mucosa and the submucosa • The most common type occurs in cecum or ascending colon of individuals over the age of 50 and is commonly known as “angiodysplasia” • Angiodysplasias account for 40% of all colonic vascular lesions and are the most common cause of lower GI bleeding in individuals over the age of 60 Angiodysplasia Hereditary Vascular Ectasia • Hereditary Hemorrhagic Telangiectasia (HHT) or Osler- Webber-Rendu disease • Systematic disease primarily involving skin and mucous membranes, and often the GI tract • Autosomal dominant disease with positive family history in 80% of cases • After epistaxis which occurs in 80% of individuals, GI bleed is the most frequent presentation and occurs in 10-40% of cases Arteriovenous Malformations (AVM’s) • Irregular meshwork of structurally abnormal medium to large ectatic vessels • Unlike small vessel ectasias, AVM’s can be distributed in all layers of the bowel wall • AVM’s may present anywhere -
Should I Send My Patient with Previous Giant Cell Arteritis for Imaging of The
Downloaded from ard.bmj.com on January 23, 2013 - Published by group.bmj.com ARD Online First, published on December 22, 2012 as 10.1136/annrheumdis-2012-202145 Clinical and epidemiological research EXTENDED REPORT Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis Sarah Louise Mackie,1 Elizabeth M A Hensor,1 Ann W Morgan,1 Colin T Pease2 ▸ Additional material is ABSTRACT together has been estimated for the Swedish popula- published online only. To view Objectives To review the literature in order to estimate tion at 0.16 per 1000 person-years in men, and 0.09 please visit the journal online (http://dx.doi.org/10.1136/ how many previously unknown thoracic aortic aneurysms per 1000 person-years in women, with a median annrheumdis-2012-202145). (TAAs) and thoracic aortic dilatations (TADs) might be age at diagnosis of 71 years and 40% overall still detected by systematic, cross-sectional aortic imaging of unruptured at diagnosis.9 Abdominal aortic aneur- 1NIHR-Leeds Musculoskeletal Biomedical Research Unit, patients with giant cell arteritis (GCA). ysm (AAA) is observed in about 5% of men over 65 10 Leeds Institute of Molecular Methods A systematic literature review was performed in ultrasound screening programmes. Medicine, Leeds, West using Ovid Medline, Embase and the Cochrane Library. Patients with GCA appear to have an elevated Yorkshire, UK Studies potentially relevant to TAA/TAD were evaluated incidence of aortic aneurysm, particularly TAA, 2Department of Rheumatology, Leeds Teaching Hospitals NHS by two authors independently for relevance, bias and compared with the general population; the aneur- Trust, Leeds, West Yorkshire, heterogeneity. -
Survival After Aortic Dissection in Giant Cell Arteritis
332 Letters to the editor pressure or hypotensive episodes were technique and rating scale for abnormalities of the thorax, without intravenous contrast seen in scleroderma and related disorders. recorded during the trial. Among the side Arthritis Rheum 1981; 24: 1159-65. medium (because of asthma), showed a effects, mild flushing (35%) and headache 9 Ferri C, La Civita L, Zignego A et al. Plasma normal mediastinum but a small rim of L, Ann Rheum Dis: first published as 10.1136/ard.55.5.332 on 1 May 1996. Downloaded from (24%) were the most frequent in isradipine levels of endothelin-I in mixed cryoglobulin- pleural fluid on the left. aemia patients. Br J Rheumatol 1994; 33: recipients. 689-90. At follow up, the patient complained of This study has demonstrated the favour- 10 Yanagisawa M, Kurihara H, Kimura S, et al. A right thigh claudication. Radiofemoral delay able effects of isradipine on patients with novel potent vasoconstrictor peptide pro- was noted. CT of the abdomen showed Raynaud's phenomenon; moreover, it is the duced by vascular endothelial cells. Nature internal displacement ofcalcified atheroma in 1988; 332: 411-5. first to demonstrate a significant reduction 11 Levin E R. Endothelins [review]. N Engl J Med the aorta, suggesting aortic dissection. Mag- in plasma concentrations of ET-1 during 1995; 333: 356-63. netic resonance imaging (MRI) confirmed calcium antagonist treatment. The most this as distal to the origin of the left sub- usual manifestations of Raynaud's phenom- clavian artery, extending to the aortic bifur- enon are pain and numbness in the fingers, cation. -
Pvd-Vs-Pad.Pdf
A CLINICIAN'S GUIDE Helping Your Patients with Peripheral Artery Disease (PAD) Peripheral Artery Disease Definition Peripheral artery disease is a disease of the blood vessels outside the heart. This condition is caused by a narrowing of vessels that carry blood away from the heart to other parts of the body. Peripheral artery disease (PAD) is often used interchangeably with the term “peripheral vascular disease (PVD).” The term “PAD” is recommended to describe this condition because it includes venous in addition to arterial disorders. PAD stems from structural changes in the blood vessels resulting from fatty buildup (atherosclerosis) in the inner walls of the arteries. These deposits hinder and block normal blood flow. Why is peripheral artery disease dangerous? In the most common type of PAD, lower extremity PAD, blood flow is reduced to the legs and feet. Left untreated, PAD can lead to gangrene and limb amputation. Patients with PAD are at heightened risk for death from both heart attack and stroke. PAD can result in poor kidney circulation, leading to high blood pressure, or blood pressure that is difficult to control with lifestyle changes and medications. In some cases, blockage of the kidney arteries may progress to loss of kidney function or kidney failure. What are the symptoms of PAD? The most common symptom of PAD is “claudication,” which is cramping, fatigue, aching, pain or discomfort in the legs and buttocks caused by poor blood circulation. The symptoms occur during activity and usually go away with rest. Claudication can often decrease the distance you can walk, and can negatively affect your ability to function at home and at work. -
Thrombosis in Vasculitis: from Pathogenesis to Treatment
Emmi et al. Thrombosis Journal (2015) 13:15 DOI 10.1186/s12959-015-0047-z REVIEW Open Access Thrombosis in vasculitis: from pathogenesis to treatment Giacomo Emmi1*†, Elena Silvestri1†, Danilo Squatrito1, Amedeo Amedei1,2, Elena Niccolai1, Mario Milco D’Elios1,2, Chiara Della Bella1, Alessia Grassi1, Matteo Becatti3, Claudia Fiorillo3, Lorenzo Emmi2, Augusto Vaglio4 and Domenico Prisco1,2 Abstract In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected. Inflammation-induced thrombosis is by now considered a feature not only of autoimmune rheumatic diseases, but also of systemic vasculitides such as Behçet’s syndrome, ANCA-associated vasculitis or giant cells arteritis, especially during active disease. These findings have important consequences in terms of management and treatment. Indeed, Behçet’syndrome requires immunosuppressive agents for vascular involvement rather than anticoagulation or antiplatelet therapy, and it is conceivable that also in ANCA-associated vasculitis or large vessel-vasculitis an aggressive anti-inflammatory treatment during active disease could reduce the risk of thrombotic events in early stages. In this review we discuss thrombosis in vasculitides, especially in Behçet’s syndrome, ANCA-associated vasculitis and large-vessel vasculitis, and provide pathogenetic and clinical clues for the different specialists involved in the care of these patients. Keywords: Inflammation-induced thrombosis, Thrombo-embolic disease, Deep vein thrombosis, ANCA associated vasculitis, Large vessel vasculitis, Behçet syndrome Introduction immunosuppressive treatment rather than anticoagulation The relationship between inflammation and thrombosis is for venous or arterial involvement [8], and perhaps one not a recent concept [1], but it has been largely investigated might speculate that also in AAV or LVV an aggressive only in recent years [2]. -
Versus Arthritis Vasculitis Information Booklet
Condition Vasculitis Vasculitis This booklet provides information and answers to your questions about this condition. Arthritis Research UK booklets are produced and printed entirely from charitable donations. What is vasculitis? Vasculitis means inflammation of the blood vessels. There are several different types of the condition, many with unknown causes, but treatments can be very effective. In this booklet we’ll briefly explain the main types of vasculitis, how they’re diagnosed and treated, what you can do to help yourself and where to get more information. At the back of this booklet you’ll find a brief glossary of medical words – we’ve underlined these when they’re first used. www.arthritisresearchuk.org Page 2 of 32 Vasculitis information booklet Arthritis Research UK What’s inside? 2 Vasculitis at a glance 5 Who diagnoses and treats 15 What is the outlook? vasculitis? 15 How is vasculitis diagnosed? 6 What is vasculitis? – What tests are there? 8 What are the symptoms 17 What treatments are there for vasculitis? of vasculitis? – Drugs 9 What types of vasculitis 20 Self-help and daily living are there? – Exercise – Takayasu arteritis (TA) – Diet and nutrition – Giant cell arteritis (temporal arteritis) – Stop smoking – Polyarteritis nodosa (PAN) – Keep warm – Kawasaki disease 22 Research and new – Granulomatosis with polyangiitis developments (Wegener’s granulomatosis) 23 Glossary – Behçet’s syndrome – Eosinophilic granulomatosis 26 Where can I find out more? with polyangiitis (Churg–Strauss 28 We’re here to help syndrome) – Microscopic polyangiitis – Cryoglobulin-associated vasculitis – Immunoglobulin A vasculitis (Henoch–Schönlein purpura) 14 Who gets vasculitis? 15 What causes vasculitis? Page 3 of 32 Vasculitis information booklet At a glance Vasculitis There are several different types of vasculitis but all are treatable. -
Giant Cell Arteritis
GIANT CELL ARTERITIS What is giant cell arteritis (GCA)? Giant cell arteritis (GCA) is a form of vasculitis—a family of rare disorders characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. Also called temporal arteritis, GCA typically affects the arteries in the neck and scalp, especially the temples. It can also affect the aorta and its large branches to the head, arms and legs. GCA is the most common form of vasculitis in adults over the age of 50. The most common symptoms of GCA include persistent, throbbing headaches, tenderness of the temples and scalp, jaw pain, fever, joint pain, and vision problems. Early treatment is vital to prevent serious complications such as blindness or stroke. GCA is typically treated with high doses of corticosteroids such as prednisone, sometimes in combination with other medications that suppress the immune system. Prompt treatment usually relieves symptoms, however GCA is a chronic condition with periods of relapse and remission, so ongoing medical care is usually necessary. Patients with GCA may also have symptoms of polymyalgia rheumatica (PMR), a closely related inflammatory disorder. Causes The cause of GCA is not yet fully understood by researchers. Vasculitis is classified as an autoimmune disorder—a disease which occurs when the body’s natural defense system mistakenly attacks healthy tissues. Researchers believe a combination of factors may trigger the inflammatory process. Studies have linked genetic factors, infectious agents, and a prior history of cardiovascular disease to the development of GCA. Who gets GCA? GCA is the most common form of vasculitis in older adults, affecting people over 50 years of age, with an average onset of 74 years of age. -
Idiopathic Peripheral Retinal Telangiectasia in Adults: a Case Series and Literature Review
Journal of Clinical Medicine Article Idiopathic Peripheral Retinal Telangiectasia in Adults: A Case Series and Literature Review Maciej Gaw˛ecki Dobry Wzrok Ophthalmological Clinic, 80-822 Gdansk, Poland; [email protected]; Tel.: +48-501-788-654 Abstract: Idiopathic peripheral retinal telangiectasia (IPT), often termed as Coats disease, can present in a milder form with the onset in adulthood. The goal of this case series study and literature review was to describe and classify different presenting forms and treatment of this entity and to review contemporary methods of its management. Six cases of adult onset IPT were described with the following phenotypes based on fundus ophthalmoscopy, fluorescein angiography, and optical coherence tomography findings: IPT without exudates or foveal involvement, IPT with peripheral exudates without foveal involvement, IPT with peripheral exudates and cystoid macular edema, and IPT with peripheral and macular hard exudates. Treatments applied in this series included observation, laser photocoagulation, and anti-vascular endothelial growth factor (VEGF) treatment with variable outcomes depending upon the extent of IPT, the aggressiveness of laser treatment, and the stringency of follow-up. The accompanying literature review suggests that ablative therapies, especially laser photocoagulation, remain the most effective treatment option in adult-onset IPT, with anti-VEGF therapy serving as an adjuvant procedure. Close follow-up is necessary to achieve and maintain reasonable good visual and morphological results. Keywords: Coats disease; peripheral retinal telangiectasia; laser photocoagulation; anti-VEGF treatment Citation: Gaw˛ecki,M. Idiopathic Peripheral Retinal Telangiectasia in 1. Introduction Adults: A Case Series and Literature Review. J. Clin. Med. 2021, 10, 1767. Idiopathic peripheral retinal telangiectasia (IPT), usually referred to as Coats disease, https://doi.org/10.3390/jcm10081767 has been well-described in the medical literature since its discovery in 1908 [1]. -
Coronary Vasculitis
biomedicines Review Coronary Vasculitis Tommaso Gori Kardiologie I and DZHK Standort Rhein-Main, Universitätsmedizin Mainz, 55131 Mainz, Germany; [email protected] Abstract: The term coronary “artery vasculitis” is used for a diverse group of diseases with a wide spectrum of manifestations and severity. Clinical manifestations may include pericarditis or my- ocarditis due to involvement of the coronary microvasculature, stenosis, aneurysm, or spontaneous dissection of large coronaries, or vascular thrombosis. As compared to common atherosclerosis, patients with coronary artery vasculitis are younger and often have a more rapid disease progression. Several clinical entities have been associated with coronary artery vasculitis, including Kawasaki’s disease, Takayasu’s arteritis, polyarteritis nodosa, ANCA-associated vasculitis, giant-cell arteritis, and more recently a Kawasaki-like syndrome associated with SARS-COV-2 infection. This review will provide a short description of these conditions, their diagnosis and therapy for use by the practicing cardiologist. Keywords: coronary artery disease; vasculitis; inflammatory diseases 1. Introduction The term vasculitis refers to a group of conditions whose pathophysiology is mediated by inflammation of blood vessels. Most forms of vasculitis are systemic and may present variable clinical manifestations, requiring a multidisciplinary approach. A number of etiologies have been reported; independently of the specific organ involvement, vasculitis Citation: Gori, T. Coronary can be primary or secondary to another autoimmune disease or can be associated with Vasculitis. Biomedicines 2021, 9, 622. other precipitants such as drugs, infections or malignancy [1]. Almost all cases of coronary https://doi.org/10.3390/ vasculitis appear as a manifestation of systemic (primary) vasculitis, which are classified biomedicines9060622 based on the type and size of the vessels affected and the cellular component responsible for the tissue infiltration.